Novartis initiates real-world study on Pluvicto in metastatic CRPC patients
Novartis is conducting a real-world study to evaluate the effectiveness of Pluvicto in metastatic CRPC patients.
Therapeutic Area
Therapeutic area intelligence for Radioligand Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.